Literature DB >> 8724709

The "cyclic" regimen of low-dose doxycycline for adult periodontitis: a preliminary study.

R J Crout1, H M Lee, K Schroeder, H Crout, N S Ramamurthy, M Wiener, L M Golub.   

Abstract

Specially-formulated low-dose doxycycline (LDD) regimens have been found to reduce collagenase activity in the gingival tissues and crevicular fluid (GCF) of adult periodontitis subjects in short-term studies. In the current, double-blind, placebo-controlled study, adult periodontitis patients were administered for 6 months a "cyclical" regimen of either LDD or placebo capsules; and various clinical parameters of periodontal disease severity, and both collagenase activity and degradation of the serum protein, alpha 1-PI, in the GCF were measured at different time periods. No significant differences between the LDD- and placebo-treated groups were observed for plaque index and gingival index. However, attachment levels, probing depth, and GCF collagenase activity and alpha 1-PI degradation were all beneficially and significantly (P < 0.05) affected by the drug regimen. We propose: 1) that LDD inhibits tissue destruction in the absence of either antimicrobial or significant anti-inflammatory efficacy; and 2) that long-term LDD could be a useful adjunct to instrumentation therapy in the management of the adult periodontitis patient.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724709     DOI: 10.1902/jop.1996.67.5.506

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  14 in total

1.  Inhibition of the activities of matrix metalloproteinases 2, 8, and 9 by chlorhexidine.

Authors:  R Gendron; D Grenier; T Sorsa; D Mayrand
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  The effect of locally delivered doxycycline as an adjunctive therapy to scaling and root planing in smokers.

Authors:  Hassan Al Hulami; Nadir Babay; Fatin Awartani; Sukumaran Anil
Journal:  Saudi Dent J       Date:  2011-05-03

3.  Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.

Authors:  Gilson C N Franco; Mikihito Kajiya; Tadashi Nakanishi; Kouji Ohta; Pedro L Rosalen; Francisco C Groppo; Cory W O Ernst; Janie L Boyesen; John D Bartlett; Philip Stashenko; Martin A Taubman; Toshihisa Kawai
Journal:  Exp Cell Res       Date:  2011-03-21       Impact factor: 3.905

Review 4.  Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature.

Authors:  Michael O Griffin; Eduardo Fricovsky; Guillermo Ceballos; Francisco Villarreal
Journal:  Am J Physiol Cell Physiol       Date:  2010-06-30       Impact factor: 4.249

Review 5.  Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic.

Authors:  Jeffrey B Payne; Lorne M Golub
Journal:  Pharmacol Res       Date:  2010-10-16       Impact factor: 7.658

6.  The Effect of Systemic Delivery of Aminoguanidine versus Doxycycline on the Resorptive Phase of Alveolar Bone Following modified Widman Flap in Diabetic Rats: A Histopathological and Scanning Electron Microscope (SEM) study.

Authors:  E Tella; S Aldahlawi; A Eldeeb; H El Gazaerly
Journal:  Int J Health Sci (Qassim)       Date:  2014-07

7.  Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial.

Authors:  R Gapski; J L Barr; D P Sarment; M G Layher; S S Socransky; W V Giannobile
Journal:  J Periodontol       Date:  2004-03       Impact factor: 6.993

Review 8.  Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm.

Authors:  Faisal Aziz; Helena Kuivaniemi
Journal:  Ann Vasc Surg       Date:  2007-05       Impact factor: 1.466

9.  Shedding of NG2 by MMP-13 attenuates anoikis.

Authors:  Nam E Joo; Di Miao; Mercedes Bermúdez; William B Stallcup; Yvonne L Kapila
Journal:  DNA Cell Biol       Date:  2014-12       Impact factor: 3.311

10.  A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair.

Authors:  Amy E Hackmann; Brian G Rubin; Luis A Sanchez; Patrick A Geraghty; Robert W Thompson; John A Curci
Journal:  J Vasc Surg       Date:  2008-07-15       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.